Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High on Strong Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)’s stock price hit a new 52-week high during mid-day trading on Thursday following a better than expected earnings announcement. The stock traded as high as $33.43 and last traded at $32.5270, with a volume of 2202319 shares traded. The stock had previously closed at $33.21.

The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 48.20% and a net margin of 8.16%.The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the company posted $0.71 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 fundamentals beat expectations — Teva reported stronger-than-expected results (reported EPS and revenue outperformed consensus), revenue grew year-over-year driven by a Sanofi milestone and Austedo growth, and management set FY‑2026 EPS guidance of roughly 2.57–2.77, supporting a higher valuation. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Barclays raised its price target to $38 and set an “overweight” rating, signaling upside from current levels and lending third‑party validation to the stock’s outlook. Barclays raises TEVA price target to $38
• Positive Sentiment: Truist increased its price target to $38 with a “buy” rating, reinforcing bullish analyst sentiment following the quarter. Truist raises TEVA price target to $38
• Positive Sentiment: Scotiabank lifted its target to $40 and moved to “sector outperform,” the highest target among recent broker notes, which may attract more investor interest. Scotiabank raises TEVA price target to $40

Analysts Set New Price Targets

Several research analysts recently weighed in on TEVA shares. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Scotiabank lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday. Barclays upped their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, Truist Financial boosted their price objective on Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the transaction, the insider owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This represents a 80.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the sale, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. This trade represents a 68.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 622,060 shares of company stock valued at $17,076,965. Corporate insiders own 0.49% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently made changes to their positions in the stock. Grove Bank & Trust grew its position in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $41,000. Cromwell Holdings LLC boosted its stake in Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares during the period. MAI Capital Management grew its holdings in Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after buying an additional 697 shares in the last quarter. Finally, Rothschild Investment LLC increased its position in shares of Teva Pharmaceutical Industries by 97.0% during the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after buying an additional 1,348 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

The business’s fifty day moving average price is $30.49 and its 200-day moving average price is $23.15. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The stock has a market capitalization of $39.09 billion, a PE ratio of 28.40, a P/E/G ratio of 1.88 and a beta of 0.66.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.